Consiglio Nazionale delle Ricerche

Tipo di prodottoArticolo in rivista
TitoloNeurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
Anno di pubblicazione2018
Formato-
Autore/iAldo Quattrone 1,2*, Gaetano Barbagallo 3, Antonio Cerasa 2,4 and A. Jon Stoessl 5
Affiliazioni autori1. Neuroscience Research Centre, University Magna Græcia, Catanzaro, Italy 2. Neuroimaging Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy 3. Institute of Neurology, University Magna Græcia, Catanzaro, Italy 4. Institute S. Anna-Research in Advanced Neurorehabilitation, Crotone, Italy 5. Pacific Parkinson's Research Centre, Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia and Vancouver Coastal Health, Vancouver, Canada
Autori CNR e affiliazioni
  • ALDO QUATTRONE
  • ANTONIO CERASA
Lingua/e
  • inglese
AbstractThe placebo effect is a phenomenon produced when an inert substance administered like a regular treatment improves the clinical outcome. Parkinson's disease (PD) is one of the main clinical disorders for which the placebo response rates are high. The first evidence of the neurobiological mechanisms underlying the placebo effect in PD stems from 2001, when de la Fuente-Fernandez and colleagues demonstrated that a placebo injection led to the release of dopamine in the striatal nuclei of PD measured with positron emission tomography technology. Since then, several studies have been conducted to investigate the neurobiological underpinnings of placebo responses. This article presents a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Of an initial yield of 143 papers, 19 were included. The lessons learned from these studies are threefold: (i) motor improvement is dependent on the activation of the entire nigrostriatal pathway induced by dopamine release in the dorsal striatum; (ii) the magnitude of placebo-induced effects is modulated by an expectancy of improvement, which is in turn related to the release of dopamine within the ventral striatum; (iii) the functioning of the neural pathways underlying the placebo response can be tuned by prior exposure and learning strategies. In conclusion, although the neural network underlying the placebo effect in PD has been largely confirmed and accepted, what remains to be established is how, when, and where the expectation of reward (mediated by the ventral striatum) interacts with the primary motor system (mediated by the dorsal striatum) to induce clinical improvement in motor symptoms.
Lingua abstractinglese
Altro abstract-
Lingua altro abstract-
Pagine da1213
Pagine a1227
Pagine totali15
RivistaMovement disorders
Attiva dal 1986
Editore: Raven Press, - [New York, N.Y.]
Paese di pubblicazione: Stati Uniti d'America
Lingua: inglese
ISSN: 0885-3185
Titolo chiave: Movement disorders
Titolo proprio: Movement disorders
Titolo abbreviato: Mov. disord.
Numero volume della rivista33
Fascicolo della rivista8
DOI10.1002/mds.27438
Verificato da referee-
Stato della pubblicazionePublished version
Indicizzazione (in banche dati controllate)
  • PubMed (Codice:30230624)
Parole chiaveParkinson's disease; dopaminergic system; dorsal-ventral pathways; pathophysiology; placebo effect
Link (URL, URI)-
Titolo parallelo-
Licenza-
Scadenza embargo-
Data di accettazione24/04/2018
Note/Altre informazioni-
Strutture CNR
  • IBFM — Istituto di bioimmagini e fisiologia molecolare
Moduli/Attività/Sottoprogetti CNR
  • DSB.AD004.039.001 : NEUROIMAGING CLINICO DEI DISORDINI NEURODEGENERATIVI DEL MOVIMENTO
Progetti Europei-
Allegati